Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
Search Results for: BGPartner
26 years after the demolition of the “Zur Linde” inn, a building permit has been granted. If all goes well, two new buildings will replace the gravel car park in the centre of the village from 2025.
In the pilot case of a PostFinance customer against PostFinance, the question is whether the customer must accept a negative balance on his account that arose due to a software error with the payment processor
The Legalcommunity Awards Switzerland 2023 took place at the AURA Event Saal in Zürich. The latest Edition brought together he excellence amongst In-House and law firms’ teams and professionals from the Swiss legal community. The
GOLDBEK Holding, a fast growing and innovative German greeting card publishing company, has acquired 100% of ABC Kunst- und Glückwunschkartenverlag (its legal name is A. Boss & Co), a privately owned Swiss market leader in
Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its
Wenger Vieli strengthens its team with four new promotions: Jonas Bühlmann (senior associate to counsel, pictured left), Meltem Steudler (associate to senior associate, pictured centre), Sabine Taxer (associate to senior associate, pictured centre-right) and
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. Through this
BGPartner has advised Araris Biotech in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures. Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the
